Table 2.
Maternal baseline data.
| Characteristic | |
|---|---|
| Age at MS diagnosis (years) | |
| Mean ± SD | 25.3 ± 5.5 |
| Range (min–max) | 18.8–34.9 |
| Age at last menstrual period (years) | |
| Mean ± SD | 30.1 ± 5.4 |
| Range (min–max) | 20.0–39.4 |
| Number of administrations of NTZ, n | |
| Mean ± SD | 22.2 ± 9.6 |
| Range (min–max) | 7–40 |
| Number of previous treatments before NTZ, n (%) | |
| No prior treatment | 0 (0) |
| 1 therapy | 7 (64) |
| 2 therapies | 4 (36) |
| >2 therapies | 0 (0) |
| Total number of relapses prior to pregnancy | |
| Mean ± SD | 7.6 ± 3.3 |
| Range (min–max) | 3–13 |
| Number of relapses within 12 months prior to pregnancy | |
| Mean ± SD | 0.36 ± 0.5 |
| Range (min–max) | 0–1 |
| EDSS 12 months prior to pregnancy | |
| Mean ± SD | 1.3 ± 1.1 |
| Range (min–max) | 0–3 |
| EDSS at pregnancy onset | |
| Mean ± SD | 1.3 ± 1.1 |
| Range (min–max) | 0–3 |
| Timing of exposure to NTZ in pregnancy, n (%) | |
| Within 8 weeks before last menstrual period | 1 (8.3) |
| First trimester | 9 (75) |
| After first trimester | 2 (16.7) |
| During all pregnancy | 0 (0) |
| Timing of exposure to NTZ in pregnancy (days) | |
| Mean ± SD | 46.2 ± 37.8 |
| Range (min–max) | −19–137 |
| Obstetric history, n (%) | |
| Primiparous | 8 (75) |
| Previous pregnancies | 4 (25) |
| Previous miscarriages/abortions | 0 (0) |
| Previous stillbirths/neonatal deaths | 0 (0) |
| Positive family history for MS, n (%) | |
| Yes | 4 (36) |
| No | 7 (64) |
| Concomitant disorders, n | |
| Thyroid cancer | 1 |
| Diabetes mellitus type I | 1 |
| Leukocytoclastic vasculitis | 1 |
| Polyarthritis | 1 |
| Vitamin-B-12 malabsorbtion deficiency | 1 |
EDSS, Expanded Disability Status Scale; max, maximum; min, minimum; n, number; NTZ, natalizumab; SD, standard deviation;%, percentage.